EUVIMEDEUVIMED entdecken
Crossref

Atorvastatin regulates hepatic transcriptome PXR dependently but distinct from pregnenolone 16α-carbonitrile and does not induce PXR-mediated liver steatosis

Heba Nabil iD, Mahmoud-Sobhy Elkhwanky iD, Mohamed Hassanen iD, Einari A Niskanen iD, Raghavendra Mysore iD, Jorma J Palvimo iD, Outi Kummu iD, Jukka Hakkola iD

Archives of Toxicology · 2026-04 · 100 (4) · 1443-1463

DOI: 10.1007/s00204-025-04280-0 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Archives of Toxicology, online erschienen am 14.01.2026. Verfasst von Heba Nabil und 7 weiteren Autor:innen. Beteiligte Einrichtung: Research Unit of Biomedicine and Internal Medicine, University of Oulu, POB 5000, 90014, Oulu, Finland. Hauptthemen laut MEDLINE: Pregnane X Receptor, Pregnenolone Carbonitrile, Atorvastatin, Liver. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 53 Literaturangaben. Gefördert von: Terveyden Tutkimuksen Toimikunta, H2020 Societal Challenges, Sydäntutkimussäätiö.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Activation of the pregnane X receptor (PXR) by various drugs promotes liver steatosis. Yet, atorvastatin, a widely prescribed statin and a PXR ligand, is considered hepatically safe, even in patients with metabolic dysfunction-associated steatotic liver disease. To reveal mechanistic differences between atorvastatin and steatosis-promoting PXR ligands we investigated whether atorvastatin elicits distinct transcriptional and epigenomic responses, and whether these underlie its favorable hepatic safety. Mice were treated orally for four days with atorvastatin, pregnenolone 16α-carbonitrile (PCN; prototypical PXR agonist), or pravastatin (a non-PXR-activating statin). Liver transcriptomics, chromatin accessibility profiling (ATAC-seq), and pathway analyses were performed. Long-term hepatic effects were assessed in high-fat diet (HFD)-fed mice after 28-day compound treatment. Atorvastatin regulated hepatic gene expression almost exclusively via PXR, yet its transcriptional signature was distinct from PCN, and atorvastatin did not induce a classical PXR-target Cyp3a11. Both ligands altered chromatin accessibility in overlapping but non-identical patterns. Atorvastatin primarily activated cholesterol biosynthesis genes, whereas PCN enriched steatosis and growth-related pathways. Atorvastatin activated both SREBP1 and SREBP2 proteins while PCN activated only SREBP1. 28-day treatment with PCN in HFD-fed mice aggravated liver steatosis while atorvastatin did not. Conversely, atorvastatin reduced hepatic Pxr expression and downregulated its classical target genes and had no longer effect on cholesterol synthesis genes. In conclusion, atorvastatin acts as a selective PXR activator, inducing a distinct hepatic transcriptional programme that avoids steatotic outcomes. These findings highlight the ligand-specific nature of PXR signaling and the hepatic safety of atorvastatin in metabolic disease contexts.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pregnane X ReceptorPregnenolone CarbonitrileAtorvastatinLiverTranscriptomeFatty LiverHydroxymethylglutaryl-CoA Reductase InhibitorsAnimalsMaleMice, Inbred C57BLMiceDiet, High-FatCytochrome P-450 CYP3AMembrane Proteins

Stichwörter der Autor:innen

ATAC-sequencingAtorvastatinCholesterol metabolismLiver steatosisPXRPregnenolone 16α-carbonitrileTranscriptomics

Substanzen

Pregnane X ReceptorPregnenolone CarbonitrileAtorvastatinHydroxymethylglutaryl-CoA Reductase InhibitorsCyp3a11 protein, mouseCytochrome P-450 CYP3AMembrane Proteins

Autor:innen und Institutionen

  • Research Unit of Biomedicine and Internal Medicine, University of Oulu, POB 5000, 90014, Oulu, Finland.
  • Medical Research Center Oulu, University of Oulu and Oulu University Hospital, Oulu, Finland.
  • Institute of Biomedicine, University of Eastern Finland, Kuopio, Finland.
  • Research Unit of Biomedicine and Internal Medicine, University of Oulu, POB 5000, 90014, Oulu, Finland. jukka.hakkola@oulu.fi.
  • Medical Research Center Oulu, University of Oulu and Oulu University Hospital, Oulu, Finland. jukka.hakkola@oulu.fi.

ORCID-Profile: Heba Nabil, Mahmoud-Sobhy Elkhwanky, Mohamed Hassanen, Einari A Niskanen, Raghavendra Mysore, Jorma J Palvimo, Outi Kummu, Jukka Hakkola

Förderung

  • Terveyden Tutkimuksen Toimikunta
  • H2020 Societal Challenges
  • Sydäntutkimussäätiö
  • Orionin Tutkimussäätiö
  • HORIZON EUROPE Marie Sklodowska-Curie Actions

Zitieren

APA

Nabil, H., Elkhwanky, M. S., Hassanen, M., Niskanen, E. A., Mysore, R., Palvimo, J. J., Kummu, O., & Hakkola, J. (2026). Atorvastatin regulates hepatic transcriptome PXR dependently but distinct from pregnenolone 16α-carbonitrile and does not induce PXR-mediated liver steatosis. Archives of Toxicology, 100(4), 1443-1463. https://doi.org/10.1007/s00204-025-04280-0

Vancouver

Nabil H, Elkhwanky MS, Hassanen M, Niskanen EA, Mysore R, Palvimo JJ, et al. Atorvastatin regulates hepatic transcriptome PXR dependently but distinct from pregnenolone 16α-carbonitrile and does not induce PXR-mediated liver steatosis. Archives of Toxicology. 2026;100(4):1443-1463. doi:10.1007/s00204-025-04280-0

BibTeX
@article{Nabil2026,
  author = {Nabil, Heba and Elkhwanky, Mahmoud-Sobhy and Hassanen, Mohamed and Niskanen, Einari A and Mysore, Raghavendra and Palvimo, Jorma J and Kummu, Outi and Hakkola, Jukka},
  title = {Atorvastatin regulates hepatic transcriptome PXR dependently but distinct from pregnenolone 16α-carbonitrile and does not induce PXR-mediated liver steatosis},
  journal = {Archives of Toxicology},
  year = {2026},
  volume = {100},
  number = {4},
  pages = {1443--1463},
  doi = {10.1007/s00204-025-04280-0}
}
Kostenlos starten →